Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06480605 in moderate to severe ulcerative colitis
NCT02840721Phase 2Completed
- Sponsor
- Telavant
- Start
- Oct 2016
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of afimkibart in ulcerative colitis (UC), sponsored by Telavant. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events, and Who Withdrew Due to Adverse Events, Number of Participants With Laboratory Abnormalities and 3 more. Started Oct 2016; status: completed.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02840721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840721.